Eurofins BioPharma Product Testing Denmark Holding A/S: Financial statements 2020
CVR: 37064408
Eurofins BioPharma Product Testing Denmark Holding A/S (CVR 37064408) has filed annual accounts for 2020. In 2020, the company reported a gross profit of DKK -79,990 and a net result of DKK 5,272,479 compared with DKK 3,326,352 the year before. Equity amounted to DKK 15,897,581. The solvency ratio was 25.7%.
- Gross Profit
- -79,990 kr.
- Profit/Loss
- 5,272,479 kr.
- Equity
- 15,897,581 kr.
- Total Assets
- 61,873,876 kr.
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2020 | - | -80 t. | 5.3 mio. | 15.9 mio. | - |
| 2019 | - | -81 t. | 3.3 mio. | 13.6 mio. | - |
| 2018 | - | -83 t. | 8.1 mio. | 15 mio. | - |
| 2017 | - | -110 t. | 910 t. | 14.4 mio. | - |
| 2016 | - | -175 t. | 584 t. | 14 mio. | - |
How creditworthy is Eurofins BioPharma Product Testing Denmark Holding A/S?
See the CDS score and get a full credit report with recommended credit limit and payment terms.
Read about the CDS scoreEvents in 2020
Eurofins BioPharma Product Testing Denmark Holding A/S has published its annual report for 2019. Gross profit came to DKK -80,588, and the net result was DKK 3,326,352.
About Eurofins BioPharma Product Testing Denmark Holding A/S
Eurofins BioPharma Product Testing Denmark Holding A/S is a Danish company of the type Aktieselskab based in Galten, founded in 2015. The company is registered under the industry Ikke-finansielle holdingselskaber. The management consists of Stefánia Pcolová. The company is owned by Eurofins Pharma Services LUX Holding SARL. In 2025, the company reported a gross profit of DKK -163,266 and a net result of DKK 8,356,614 compared with DKK -1,877,244 the year before. Equity amounted to DKK 24,787,263.
